News
-
2 min
iQure Pharma Receives Approval for iQ-007 Phase 1 First in Human Study
-
5 min
iQure Pharma’s iQ-007 Receives FDA Orphan Drug Designation for Dravet’s Syndrome
-
5 min
iQure Pharma Secures $4M Funding – Advancing Phase 1 Clinical Trial for iQ-007
-
2 min
iQ-007 Preclinical Stage Complete — Phase 1 Preparations Targeted for Q1 2025
-
2 min
iQ-007 Zebrafish Screening Reveals Positive Results in Other Neurodegenerative Diseases
-
2 min
Initial iQ-007 IND-Enabling Tox Results Accelerate Prep for First in Human Phase 1 Study
-
2 min
iQure Pharma Awarded Its First Patent for iQ-008, a Novel Analgesic Compound to Treat Pain
-
2 min
iQure Pharma Attending JPM Week in San Francisco — January 8-12, 2024
-
3 min
iQure Pharma Announces Impressive Second Close of Oversubscribed Series A Financing
-
3 min
iQure Pharma Secures Funding from Ventura BioMed Investors and OKG Capital
-
1 min
iQ-007 Accepted into Prestigious NIH Preclinical Screening Platform for Pain (PSPP) Program
